Trial Profile
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2015
Price :
$35
*
At a glance
- Drugs Lomustine (Primary) ; Sunitinib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 22 Oct 2015 New trial record
- 01 Oct 2015 Results presented in Anticancer Research.